India Considers Overriding Cancer Drug Patents

Law360, New York (February 27, 2008, 12:00 AM EST) -- Entering the bullpen once again, India is taking up the issue of how to balance patent protection with patient need, with the country's patent office reportedly set to consider this week whether to override patents on cancer drugs made by Pfizer Inc. and Roche AG and to allow a generics maker to ship copycat versions to Nepal for distribution.

The case centers on whether the Hyderabad-based Natco Pharma should be allowed to manufacture Erlotinib, patented in India by the Swiss drugmaker Roche under the brand name...
To view the full article, register now.